531 results about "Platelet" patented technology

The invention discloses a kit and a method for HLA cross reaction group and HPA genotyping. The system for HLA cross reaction group and HPA genotyping detection is obtained through respective combination design of two different primers on the basis of common specific SNP loci, and rapid, simple, low-cost and high-throughput HLA epitope and HPA genotyping detection can be realized, so that platelet infusion ineffectiveness and immune platelet infusion ineffectiveness are more effectively prevented.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention discloses a traditional Chinese medicine composition with an effect of improving artery blood vessel plaque and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The technical problem to be solved is to provide a traditional Chinese medicine composition capable of improving vascular plaques such as carotid artery, aortic arch, brachial trunk, subclavian artery and the like aiming at the current situation that adverse reactions exist when statin lipid-lowering drugs and antiplatelet drugs are taken for a long time to treat artery vascular plaques. According to the technical scheme, the traditional Chinese medicine composition with the effect of improving the artery blood vessel plaque is characterized by comprising radix puerariae, red yeast rice, folium cortex eucommiae, hippophae rhamnoides leaves and natto.

Disclosed are platelet-derived extracellular vesicles (EVs), and composite materials comprising them, for use as bone replacement material and / or as bone rebuilding material. Also, methods of production, medical uses and kits are disclosed.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

The present disclosure relates to methods for making platelet derived human growth factor concentrate and related therapeutic and pharmaceutical compositions and uses thereof. Methods of use of the therapeutic and pharmaceutical compositions are also provided herein.

The application belongs to the technical field of biomedical engineering, and particularly relates to a micro-hydrogel wrapping platelets, a freeze-dried powder and a preparation method, use method and application thereof. The micro-hydrogel wrapping platelets, the micro-hydrogel is in a core-shell or multi-chamber structure, and the platelets are wrapped inside; the micro-hydrogel is formed by emulsifying a dispersed phase solution in a continuous phase solution and spontaneously physically gelling, and the platelets are wrapped inside; the micro-hydrogel can reduce the damage to the platelets caused by the freeze-drying process and rehydration, and the platelets can be stored for a long time after freeze-drying; when used, the micro-hydrogel can be dissociated by only rehydrating, centrifuging and heating, without the need of adding an additional decrosslinking agent, and the operation is convenient. The micro-hydrogel wrapping platelets has higher expression of hemostasis-related glycoprotein and lower de-sialylation degree after freeze-drying, rehydration and dissociation, and is expected to have better hemostasis ability and longer in-vivo circulation time; and is expected to greatly extend the storage time of platelets and alleviate the shortage of platelets.

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

Disclosed are platelet-derived extracellular vesicles (EVs), and composite materials comprising them, for use as bone replacement material and / or as bone rebuilding material. Also, methods of production, medical uses and kits are disclosed.

The invention discloses a platelet growth factor derived polypeptide as well as a composition and application thereof. The amino acid sequence of the polypeptide is shown as Seq ID No: 1 (RP1601: LLKLLKKLLKKLLKK). KKIIKKL is used as a core active sequence, a variant library is designed by adopting a special design rule (AABB cycle rule), optimization is carried out by combining a polypeptide activity prediction system with a molecular docking technology, finally five candidate polypeptides are screened out, the polypeptide RP1601 has a better balance expression between drug effect and safety, and the polypeptide RP1601 is simple in structure, easy to synthesize and optimize and high in stability, and can be used for preparing a polypeptide RP1601. Therefore, the polypeptide is determined as an optimal candidate polypeptide; based on excellent anti-inflammatory, repair-promoting and anti-oxidation characteristics of the polypeptide, the invention further provides application of the polypeptide in cosmetics and medicines.

The invention provides a docetaxel-loaded platelet delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, the docetaxel-loaded platelet delivery system is obtained by loading the docetaxel with the platelets for the first time, so that the problem that in the prior art, the traditional docetaxel preparation (injection) needs to be solubilized by polysorbate 80, so that allergy is easily caused is avoided, the safety and biocompatibility of the docetaxel medicine are improved, and the docetaxel-loaded platelet delivery system is suitable for clinical application. And the docetaxel-loaded platelet delivery system has excellent stability and can be stored at normal temperature for a long time. The invention provides the preparation method of the docetaxel-loaded platelet delivery system, and the method is simple to operate, high in encapsulation efficiency and drug loading rate and suitable for popularization. The docetaxel-loaded platelet delivery system disclosed by the invention has an outstanding treatment effect on melanoma and has a good application prospect.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The present disclosure relates to methods for making platelet derived human growth factor concentrate and related therapeutic and pharmaceutical compositions and uses thereof. Methods of use of the therapeutic and pharmaceutical compositions are also provided herein.

The invention relates to an extraction and culture method of urine-derived stem cells, and belongs to the field of cell biology and regenerative medicine. The method comprises the following steps: coating a culture plate with a gelatin solution; collecting clean midstream urine of healthy people and adding antibiotics; centrifugally separating the cell precipitate; washing with a phosphate buffer solution; re-suspending the precipitate by using a urine stem cell complete culture medium for primary culture; and after the cells grow to a certain fusion degree, carrying out passage amplification. The urine stem cell complete medium comprises a basic medium, fetal calf serum, epidermal growth factors, platelet-derived growth factors and basic fibroblast growth factors. By adopting the method disclosed by the invention, the urine-derived stem cells can be efficiently and stably separated from urine, and the obtained cells have high multiplication capacity, good stemness maintaining capacity, multidirectional differentiation potential and immunoregulation function, and can provide an ideal seed cell source for treating diseases such as diabetic erectile dysfunction.

The invention belongs to the technical field of medical biomaterial engineering application, and particularly relates to a bone repair scaffold for promoting diabetic bone defect repair. The stent main body is provided with a functional material, and the functional material comprises one or a combination of more than two of the following components: platelet-derived growth factors, copper ions and strontium ions; the weight part ratio of the platelet-derived growth factor to the copper ions to the strontium ions is (0.001-0.1): (0.005-1): (0.01-10). According to the bone repair scaffold provided by the invention, through the synergistic effect of the platelet-derived growth factor (PDGF-BB) and trace metal copper and strontium, the bone defect and osteoporotic bone defect of a diabetic patient are treated.

The invention belongs to the field of biological materials, and particularly relates to hydroxyapatite nanofiber / biopolymer composite hemostatic sponge capable of rapidly absorbing liquid and expanding as well as a preparation method and application of the hydroxyapatite nanofiber / biopolymer composite hemostatic sponge. The hemostatic sponge is formed by cross-linking and compounding hydroxyapatite nanofibers and biopolymers, the chemical composition of the hydroxyapatite nanofiber is hydroxyapatite, the diameter of the hydroxyapatite nanofiber is 10-100 nm, and the length of the hydroxyapatite nanofiber is 10-500 [mu] m; the biopolymer is one or more of chitosan, carboxymethyl chitosan, hydroxypropyl chitosan, chitosan quaternary ammonium salt, chitosan hydrochloride, hyaluronic acid, alginic acid, gelatin and collagen; the hydroxyapatite nanofiber in the hemostatic sponge accounts for 10wt%-90wt% of the total mass of the sponge. The hemostatic sponge disclosed by the invention has excellent imbibition expansion capacity, relatively high imbibition expansion pressure, good erythrocyte and platelet adsorption capacity and good blood compatibility and biocompatibility.

The invention relates to the technical field of biological detection, and particularly discloses an ELISA kit for detecting a neutralizing antibody of a severe fever with thrombocytopenia syndrome virus and an application method of the ELISA kit. The ELISA kit comprises an ELISA plate on which SFTSV receptor LRP1 protein is fixed, and an enzyme-labeled SFTSV Gn-8M, wherein the SFTSV receptor LRP1 protein is fixed on the ELISA plate; the SFTSV Gn-8M is an SFTSV membrane protein Gn mutant designed by the invention, and can be specifically combined with an SFTSV receptor LRP1 protein on an elisa plate, and compared with a standard virus strain Gn protein, the self-designed SFTSV Gn-8M has amino acid mutation of eight sites, has stronger combining capacity with a host cell receptor, and can be used for detecting the SFTSV. The kit disclosed by the invention has the characteristics of high safety, high efficiency, high flux, high specificity, high sensitivity, high stability and the like, and is suitable for large-scale rapid screening of the neutralizing antibody of the severe fever with thrombocytopenia syndrome virus.

The invention provides a developmental growth plate layered stent as well as a preparation method and application thereof, and belongs to the technical field of bone tissue engineering materials. The developmental growth plate layered stent provided by the invention is divided into three layers, the upper layer is a cartilage cell layer, the middle layer is a blood vessel barrier layer, and the lower layer is an ossification layer. The blood vessel barrier layer can be used as biological glue to bond the upper layer and the lower layer, so that the composite stent is stable in structure and not easy to break; the upper layer contains bone marrow mesenchymal stem cells (BMSCs), and the middle layer and the lower layer are free of cells. Under the condition of in-vitro chondrogenesis induction culture, the BMSCs on the upper layer can penetrate through the middle layer and be colonized on the lower layer, and in the process, part of the BMSCs can be differentiated into cartilage cells. The middle layer containing the platelet reaction protein 1 (TSP1) has a specific intervention effect on cell migration, which is expressed by inhibiting the migration of vascular endothelial cells, but has no influence on the migration of the BMSCs.

The present disclosure relates to methods of reducing the risk of thrombosis with thrombocytopenia syndrome (TTS) associated with adenoviral vector therapy.

The application discloses an evaluation method for predicting the safety of EGFR TKIs monotherapy for NSCLC. The method comprises the following steps: obtaining the data of a plurality of patients receiving EGFR TKIs treatment; taking MDRAE (maximum grade of drug-related adverse event) as a safety index, constructing a safety evaluation final model, and the final model is an ordered logistic regression model, the covariates of the final model include normalized steady-state trough concentration, EGFR TKIs treatment history, gender, baseline glutamyltransferase, baseline uric acid, baseline creatine kinase, baseline platelets and baseline lymphocytes; obtaining the data of a target patient, inputting the numerical values of each covariate in the data of the target patient into the final model; determining the first probability of MDRAE of the target patient being grade 3 and above, the second probability of MDRAE being grade 2 and the third probability of MDRAE being grade 1 and below according to the final model, and taking the grade corresponding to the maximum probability in the three probabilities as the predicted grade of MDRAE of the target patient. The application improves the accuracy of predicting the safety of EGFR TKIs monotherapy for NSCLC.

The invention belongs to the technical field of biological medicine, and provides an antibody targeting Gn glycoprotein on the surface of a severe fever with thrombocytopenia syndrome virus and application of the antibody. The antibodies N2C1 and N2D2 and the bispecific antibody obtained by modification based on the antibodies N2C1 and N2D2 provided by the invention can be specifically combined with Gn glycoprotein on the surface of the severe fever with thrombocytopenia syndrome virus, and show a strong neutralization protection effect in in-vitro cell and in-vivo animal experiments. Therefore, the N2C1 and N2D2 antibodies and the bispecific antibody obtained by modification can be used as drugs for preventing or treating severe fever with thrombocytopenia syndrome virus infection.

In one aspect, the invention provides compositions and methods for preventing, reducing, and / or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and / or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and / or antithrombosis and / or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The invention discloses a lipid nanoparticle-platelet conjugate as well as a preparation method and application thereof. The conjugate is formed by coupling lipid nanoparticles and platelets through a covalent modification method, a non-covalent modification method or a genetic engineering method, and the lipid nanoparticles can be loaded with nucleic acid, small molecules, protein / polypeptide drugs or CRISPR / Cas system components. The lipid nanoparticles have the drug carrying function of lipid nanoparticles and the natural spleen targeting characteristic of platelets, and the drug uptake rate and delivery efficiency of immune cells can be improved. The preparation method adopts manual mixing, ethanol injection or a microfluidic method, is simple, convenient and efficient, can be completed within several minutes, and does not damage platelets. According to the conjugate, the drug loading type and the coupling mode can be adjusted according to different diseases, the limitation of a single drug carrier is broken through, and the conjugate can adapt to various scenes such as tumor treatment and vaccine delivery and meet the personalized treatment requirement.

Methods and kits for mitigating lung injury in a subject treated with a targeted radiation therapy or otherwise exposed to radiation are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced lung injury.

An example system for detecting and quantifying drug and / or chemical interactions with a biological sample is provided. The system includes a detection instrument with computing capability. The system includes an assay device capable of receiving a biological sample. Introduction of the biological sample into the assay device results in a biological process by which fibrin and platelets may accumulate at a reaction zone of the assay device. The assay device is capable of receiving one or more chemical reagents and one or more drug reagents. The fibrin and platelets, and their associated signals, accumulated at the reaction zone of the assay device are usable to determine at least one of a drug presence, a drug class, a drug level in relation to a threshold, or a drug concentration, within the biological sample.

The present invention relates to improved platelet-derived growth factor (PDGF) polypeptide variants, particularly polypeptides comprising the sequence of any one of SEQ ID NOs: 2 to 4 or a sequence having at least 80% similarity thereto, wherein the PDGF polypeptide exhibits increased stability, biological activity and / or solubility compared to the wild-type PDGF polypeptide of SEQ ID NO: 1. The present invention further provides nucleic acid sequences encoding the PDGF polypeptides of the present invention, and also provides a method for growing animal cells, comprising culturing the animal cells in a culture medium containing the PDGF polypeptide of the present invention.

The present application relates to the application of traditional Chinese medicine active ingredient composition and its preparation in synergistic anti-tumor of PD-1 inhibitor. The traditional Chinese medicine active ingredient composition is a composition of oxymatrine and astragaloside B. The combination of the two can improve the anti-tumor effect of PD-1 inhibitor. In addition, it can also be used in the form of preparation to realize in vivo drug delivery in cooperation with its pharmaceutically acceptable carrier. The carrier can be selected from iron-based MOF and liposome, etc. to realize the co-loading of oxymatrine and astragaloside B with different polarity and efficient drug delivery. The iron-based MOF carrier has the advantages of high drug loading capacity and Fe ion which can cooperate with astragaloside B to improve the activity of tumor infiltrating T cells. The ferromagnetism and platelet membrane modification can also precisely target tumor tissue. The preparation technology of liposome is mature, which is conducive to industrialized production and has broad prospects for clinical transformation. The combination of the two with PD-1 inhibitor can significantly improve the anti-tumor effect of PD-1 inhibitor.

The present disclosure relates to a use of Herombopag or a pharmaceutically acceptable salt thereof in treatment of tumor chemotherapy-induced thrombocytopenia. Specifically, the present disclosure relates to a disease treatment method, comprising: administering to a patient Herombopag or a pharmaceutically acceptable salt thereof, which can significantly increase the blood platelet count of a subject.